Broadcast

A New Momentum for Renal Denervation: 2023 ESH Guidelines

Joost Daemen,

Watch time: 1h 12m 46s

Broadcast

Treating Hypertension With uRDN

Atul Pathak, Joost Daemen, Joachim Weil, et al

Watch time: 1h 11s

Broadcast

The Science of Ultrasound Renal Denervation

Philipp Lurz, Michael Joner, Felix Mahfoud, et al

Watch time: 57m 24s

Broadcast

Renal Denervation in the Real World

Michel Burnier, Roland E Schmieder, , et al

Watch time: 1h 4m 59s

Broadcast

Treating Hypertension With uRDN

Atul Pathak, Joost Daemen, Joachim Weil, et al

Watch time: 1h 11s

Broadcast

The Future of Hypertension Management - Renal Denervation Provides Another…

Justin E Davies, Faisal Sharif

Watch time: 59m 59s

Broadcast

A New Momentum for Renal Denervation: 2023 ESH Guidelines

Joost Daemen,

Watch time: 1h 12m 46s

About

Hypertension is the most common modifiable risk factor for cardiovascular disease and death, and lowering blood pressure with antihypertensive drugs reduces target organ damage and prevents cardiovascular disease outcomes.

Most hypertensive patients will need a combination of antihypertensive agents to achieve the therapeutic goals. Recent guidelines recommend initiating treatment with two drugs in those patients with a systolic blood pressure >20 mmHg and/or a diastolic blood pressure >10 mmHg above the goals, and in those patients with high cardiovascular risk. In addition, approximately 25% of patients will require three antihypertensive agents to achieve the therapeutic targets.

Articles

Renal Denervation: A Practical Guide

Published:

07 March 2023

Citation:

Interventional Cardiology 2023;18:e06.

Balloon Pulmonary Angioplasty: State of the Art

Published:

15 February 2021

Citation:

Interventional Cardiology Review 2021;16:e02.

Interventional Therapies for Resistant Hypertension: A Brief Update

Citation:

Interventional Cardiology Review 2016;11(1):64–9

Vascular Access and Chronic Total Occlusion Angioplasty

Citation:

Interventional Cardiology Review 2015;10(2):90–3